Oncology Peer Review On-The-Go: 1-on-1 with Che-Kai Tsao, MD on Smoking Cessation and Patient Screening

Podcast

The latest episode of CancerNetwork’s podcast features an exclusive conversation with an industry thought leader regarding smoking cessation and its impact on patients with cancer.

In the first episode of 2021, CancerNetwork® spoke with Che-Kai Tsao, MD, a medical oncologist at Mount Sinai, about smoking cessation, its relation to cancer, and patient screening programs. Moreover, he went into detail regarding a National Cancer Institute–funded smoking cessation program, known as the Cancer Center Cessation Initiative, which is an initiative that Mount Sinai has been a part of for a number of years.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Recent Videos
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Related Content